Kodiak Sciences to Present at Three Upcoming Investor Conferences
Kodiak Sciences to Present at Three Upcoming Investor Conferences
PR Newswire
PALO ALTO, Calif., Nov. 11, 2026
PALO ALTO, Calif., Nov. 11, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D., Chief Executive Officer, will present at the following investor conferences in November and December 2026:
- Jefferies Global Healthcare Conference
Monday, November 16, 2026
12:30 – 12:55 PM GMT
London, UK - UBS Global Biopharma Conference
Tuesday, November 17, 2026
9:20 – 9:50 AM GMT
London, UK - 9th Annual Evercore Healthcare Conference
Tuesday, December 1, 2026
7:55 – 8:15 AM ET
Miami, FL
Live webcasts of the presentations will be available in the "Events and Presentations" section of Kodiak's investor relations website at http://ir.kodiak.com/. Replays will be available for a limited time following each presentation.
About Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a pre-commercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next-generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs. Zenkuda™ (tarcocimab tedromer) has a BLA-ready profile in wet age-related macular degeneration (wet AMD), diabetic retinopathy and retinal vein occlusion. KSI-501 is being evaluated in wet AMD and diabetic macular edema. Zenkuda and KSI-501 target the $15 billion anti-VEGF market across retinal vascular diseases. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026 and for Pivotal Analysis 2 (PEAK+PINNACLE) in 2Q 2027.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the timing of topline data readouts from the PEAK and PINNACLE Phase 3 studies. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled "Risk Factors" in Kodiak's Annual Report on Form 10-K for the year ended December 31, 2025 as well as discussions of potential risks, uncertainties, and other important factors in Kodiak's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date presented, and Kodiak undertakes no duty to update such information unless required by law.
Kodiak®, Kodiak Sciences® and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
SOURCE Kodiak Sciences Inc.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Growth Stocks to Buy While They’re Still Undervalued
3 of the Best Core Stocks to Own
3 Great New ETFs From 2026
Retirees: 5 Reasons to Consider Index Funds and ETFs
United States